Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04420273 · ClinicalTrials.gov registry record · NA
Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access
A NA study of Melanoma, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT04420273 is a NA study of Melanoma that has completed, run by Northwestern University. The registered enrollment target is 1,000 participants, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04420273, a NA study of Melanoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to reduce melanoma mortality by improving early detection of melanoma with skin self-examination (SSE) among people who self-identify as being at risk and seek care for a concerning mole. Because women are more likely than men to perform SSE, women who are engaged in health promotion by having a recent screening mammogram are the focus of this research. Self-management of melanoma detection with SSE depends on ready access to dermatologists when a concerning mole is detected. In March 2020, the Illinois stay at home order (COVID-19) prohibited non-essential health care, including screening mammography and dermatology office-based care, and both are expected to remain limited until fall 2020. This submission explores a) the effectiveness of targeted melanoma detection (TMD) among women, who identify their risk of having a melanoma, learn to perform SSE, and perform SSE, and b) the effectiveness of adhesive patch-based home sample collection for genomic analysis to rule out melanoma in moles identified by women (who received the intervention) as concerning will be explored.
Conditions Studied
Interventions
- BEHAVIORAL SSE educational intervention
- BEHAVIORAL Active control:Healthy Living
Study Locations (1)
Illinois
- Northwestern University Feinberg School of Medicine Department of Dermatology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-07-02 |
| Est. Completion | 2021-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04420273
The ClinicalTrials.gov registry entry for NCT04420273 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (42% higher). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which SSE educational intervention is the first listed.
NCT04420273 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04420273 about?
NCT04420273 is a clinical study titled "Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access". The purpose of this study is to reduce melanoma mortality by improving early detection of melanoma with skin self-examination (SSE) among people who self-identify as being at risk and seek care for a concerning mole. Because women are more likely than men to perform SSE, women who are engaged in hea...
What is the current status of trial NCT04420273?
This trial is currently completed. It is a NA study. The enrollment target is 1,000 participants. The study started on 2020-07-02. Estimated completion is 2021-03-01.
What conditions does trial NCT04420273 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04420273?
The interventions under investigation include: SSE educational intervention (BEHAVIORAL), Active control:Healthy Living (BEHAVIORAL).
Who is sponsoring clinical trial NCT04420273?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04420273 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
RECRUITING · NA
-
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
RECRUITING · NA
-
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.